Cytosorbents Corporation’s CTSO share price has dipped by 5.17%, which has investors questioning if this is right time to buy ...

CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical ...

CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval ...

PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (CTSO) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ...

"We are grateful for the opportunity to once again collaborate with the New Jersey Economic Development Authority to convert our state NOLs and R&D tax credits into non-dilutive funding that ...

CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 ...

Shares of CTSO stock opened at $1.03 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market capitalization of $64.38 ...

CytoSorbents以其用于重症监护和心脏手术的血液净化技术而闻名。其主打产品CytoSorb®在70多个国家销售，全球已使用超过27万例。公司目前正在寻求DrugSorb™-ATR在美国和加拿大的批准，该产品旨在减少手术期间与血液稀释剂相关的出血。公司展示了14.51%的可观收入 ...